open access

Vol 3, No 1 (2002): Practical Diabetology
Research paper
Published online: 2001-12-06
Get Citation

Assessment of applicability of NovoNorm as a first line therapy in type 2 diabetes patient in General Practitioner practice

Janusz Krzymień, Maciej Nazar
Diabetologia Praktyczna 2002;3(1):9-16.

open access

Vol 3, No 1 (2002): Practical Diabetology
Original articles (submitted)
Published online: 2001-12-06

Abstract

INTRODUCTION. NovoNorm is effective first line treatment in type 2 diabetes. Its mechanism of action is primarily prandial glucose regulation. This leads to good tolerance, easy dosing, simple application regimen and less hypoglycemic reactions. Those features make Novo Norm interesting choice for both patients and doctors. The aim of this study was the evaluation of the applicability of NovoNorm in general practitioner practice.
MATERIAL AND METHODS. 25 weeks prospective trial included 168 type 2 diabetes patients and 36 general practitioner practices. Efficacy of Novo Norm wasassessed using endpoints as HbA1c change from baseline, fasting plasma glucose and 7-point glycemia profile. Safety was assessed as the number of hypoglycemic
symptom episodes. Furthermore, adherence to treatment (as an index based on drug accountability and patient diary) and treatment satisfaction from patient (DTSQ questionnaire) and doctor (D-SAT questionnaire) perspective were also assessed.
RESULTS. FPG and HbA1c reduction during 25 weeks of treatment with NovoNorm were not only statistically significant but also clinically relevant. Mean value of FPG during screening visit was 158.96 mg/dl and reduced to 123.29 mg/dl (HbA1c 7.45% to 6.51 respectively). Efficacy of the drug was assessed as high in over 95 responses.
CONCLUSIONS. The results based on doctors and patients evaluation point at the fact that new concept of diabetes treatment namely prandial glucose regulation is fully accepted and NovoNorm is a useful option for treatment of type 2 diabetes.

Abstract

INTRODUCTION. NovoNorm is effective first line treatment in type 2 diabetes. Its mechanism of action is primarily prandial glucose regulation. This leads to good tolerance, easy dosing, simple application regimen and less hypoglycemic reactions. Those features make Novo Norm interesting choice for both patients and doctors. The aim of this study was the evaluation of the applicability of NovoNorm in general practitioner practice.
MATERIAL AND METHODS. 25 weeks prospective trial included 168 type 2 diabetes patients and 36 general practitioner practices. Efficacy of Novo Norm wasassessed using endpoints as HbA1c change from baseline, fasting plasma glucose and 7-point glycemia profile. Safety was assessed as the number of hypoglycemic
symptom episodes. Furthermore, adherence to treatment (as an index based on drug accountability and patient diary) and treatment satisfaction from patient (DTSQ questionnaire) and doctor (D-SAT questionnaire) perspective were also assessed.
RESULTS. FPG and HbA1c reduction during 25 weeks of treatment with NovoNorm were not only statistically significant but also clinically relevant. Mean value of FPG during screening visit was 158.96 mg/dl and reduced to 123.29 mg/dl (HbA1c 7.45% to 6.51 respectively). Efficacy of the drug was assessed as high in over 95 responses.
CONCLUSIONS. The results based on doctors and patients evaluation point at the fact that new concept of diabetes treatment namely prandial glucose regulation is fully accepted and NovoNorm is a useful option for treatment of type 2 diabetes.
Get Citation

Keywords

type 2 diabetes; prandial glucose regulation

About this article
Title

Assessment of applicability of NovoNorm as a first line therapy in type 2 diabetes patient in General Practitioner practice

Journal

Clinical Diabetology

Issue

Vol 3, No 1 (2002): Practical Diabetology

Article type

Research paper

Pages

9-16

Published online

2001-12-06

Bibliographic record

Diabetologia Praktyczna 2002;3(1):9-16.

Keywords

type 2 diabetes
prandial glucose regulation

Authors

Janusz Krzymień
Maciej Nazar

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl